Table 1.

Patients characteristics at the time of transplant

No	Age at TX	Sex	Disease	Stage at TX	Previous treatments	Disease status at the time of TX
1	66	F	SS	IVA2	IFN plus Bexarotene, ECP	Untested relapse
2	54	M	SS	IVA1	IFN plus Bexarotene, TSEB, Caelyx	Refractory
3	59	M	MF	IVA2	PUVA, IFN, Bexarotene, Gemcitabine, Brentuximab, TSEB	Refractory
4	55	F	MF	IIB	PUVA, IFN, Bexarotene, Gemcitabine, Brentuximab, TSEB	Refractory
5	59	F	MF	IIIA	PUVA, IFN, Gemcitabine, Brentuximab	Refractory LCT*
6	37	M	MF	IIIB	PUVA, IFN, Bexarotene, Gemcitabine, TSEB	Refractory
7	67	M	MF	IVA1	PUVA, IFN, Caelyx, CHOP, Chlorambucil, Brentuximab	Refractory
8	71	F	MF	IVA1	PUVA, IFN, Brentuximab, TSEB	Refractory
9	59	F	MF	IIB	PUVA, IFN, Brentuximab, Gemcitabine, Caelyx	Refractory LCT*
10	57	M	MF	IIB	CHOP, Auto-SCT, Caelyx, Gemcitabine	Refractory

TX, Transplant; IFN, Interferon; ECP, Extracorporeal photopheresis; TSEB, Total skin electron beam;

^*LCT, Large cell transformation in skin lesions.